It is speculated that MDM2 PROTACs may permit more efficacious engagement and selective destruction of MDM2 protein in NSCLC cells, and combining MDM2 PROTACs and targeted therapy would be a promising strategy to overcome resistance to Osimertinib in patients with EGFR mutant NSCLC. This evidence concerns the gene MDM2 and non-small cell lung carcinoma.